Four months after securing $125 million in funding, SpringWorks Therapeutics is eying another $115 million from a potential initial public offering.
Pfizer Spins Off Four of Its Best Drug Candidates Into a Startup With $103 Million
Big Pharma, Biotech, FAAH Inhibitors, Gamma-Secretase Inhibitors, Genetic Diseases, Hereditary Xerocytosis, MEK Inhibitors, Neurofibromatosis, Post-Traumatic Stress Disorder, Product Pipelines, Rare Diseases, Rare Disorders, Red Blood Cell, Science, Startups, TumorsPfizer launched a six-person biotech startup, SpringWorks Therapeutics, with a $103 million Series A financing. Joining Pfizer in funding the company was Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed and LifeArc, formerly known as MRC Technology.